Therapeutic targeting of EGFR in colorectal cancer as a novel approach to predict and enhance tumor antigenicity and response to checkpoint inhibitors
Duration: 54 months, Funding volume: € 999,500
Geräte und Software für Core Facilities
Funding volume: € 61,255